帕瑞昔布联合表柔比星对乳腺癌MCF-7细胞增殖和迁移的影响
|
摘要
目的研究帕瑞昔布联合表柔比星对乳腺癌MCF-7细胞增殖和迁移的影响。方法选用乳腺癌MCF-7细胞株,分为4组:对照组、帕瑞昔布组、表柔比星组、联合用药组。对照组用RPMI-1640完全培养液100μL处理,帕瑞昔布组用100μmol·L~(-1)帕瑞昔布溶液100μL处理,表柔比星组用0.25 mg·L~(-1)表柔比星溶液100μL处理,联合用药组=帕瑞昔布组+表柔比星组。用四甲基偶氮唑盐比色法检测细胞增殖抑制率,用流式细胞术检测细胞凋亡率和细胞周期,用细胞划痕实验检测细胞迁移能力,用实时定量聚合酶链反应检测细胞microRNA-199a/b-3p表达水平。结果药物处理后,对照组、帕瑞昔布组、表柔比星组、联合用药组的细胞凋亡率分别是(4.73±0.58)%,(18.95±2.17)%,(16.74±2.08)%和(53.25±6.53)%,这4组的细胞迁移率分别是(58.63±7.36)%,(41.54±4.35)%,(38.36±4.42)%和(19.17±2.23)%,这4组的microRNA-199a/b-3p表达水平分别是(0.49±0.06),(1.18±0.16),(1.22±0.13)和(1.98±0.25)2~(-ΔΔCt),表柔比星组与对照组比较,差异均有统计学意义(均P<0.05);帕瑞昔布组、联合用药组与表柔比星组比较,差异均有统计学意义(均P<0.05)。结论帕瑞昔布联合表柔比星能通过上调microRNA-199a/b-3p表达水平及阻滞细胞周期有效地抑制乳腺癌MCF-7细胞增殖和迁移。
Objective To study the effect of parecoxib combined with adriamycin on the proliferation and migration in breast cancer MCF-7cell.Methods Breast cancer MCF-7 cells were selected and divided into 4 groups:control group,parecoxib group,adriamycin group and combined medication group.The control group was treated with RPMI-1640 complete culture solution 100μL,the parecoxib group was treated with 100μmol·L~(-1)parecoxib solution 100μL,the adriamycin group was treated with 0.25 mg·L~(-1)adriamycin solution 100μL,the combined medication group=the parecoxib group+the adriamycin group.The cell proliferation inhibition rate was detected by tetrazolium salt colorimetry assay.The flow cytometry was used to detect apoptosis rate and cell cycle.The cell migration ability was detected by cell scratch test.The expression level of microRNA-199a/b-3p was detected by quantitative real-time polymerase chain reaction.Results After medication,the apoptosis rates in control group,parecoxib group,adriamycin group and combined medication group were respectively(4.73±0.58)%,(18.95±2.17)%,(16.74±2.08)%and(53.25±6.53)%;the migration rates in the 4 groups were respectively(58.63±7.36)%,(41.54±4.35)%,(38.36±4.42)%and(19.17±2.23)%;the expression of microRNA-199a/b-3p in the 4 groups were respectively(0.49±0.06),(1.18±0.16),(1.22±0.13)and(1.98±0.25)2~(-ΔΔCt).Compared between the control group with the the adriamycin group,the difference was statistically significant(all P<0.05);compared between the adriamycin group with parecoxib group and combined treatment group,the differences were both statistically significant(both P<0.05).Conclusion Parecoxib combined with adriamycin can effectively inhibit the proliferation and migration of breast cancer MCF-7 cells by up-regulating the expression of microRNA-199a/b-3p and blocking cell cycle.
Objective To study the effect of parecoxib combined with adriamycin on the proliferation and migration in breast cancer MCF-7cell.Methods Breast cancer MCF-7 cells were selected and divided into 4 groups:control group,parecoxib group,adriamycin group and combined medication group.The control group was treated with RPMI-1640 complete culture solution 100μL,the parecoxib group was treated with 100μmol·L~(-1)parecoxib solution 100μL,the adriamycin group was treated with 0.25 mg·L~(-1)adriamycin solution 100μL,the combined medication group=the parecoxib group+the adriamycin group.The cell proliferation inhibition rate was detected by tetrazolium salt colorimetry assay.The flow cytometry was used to detect apoptosis rate and cell cycle.The cell migration ability was detected by cell scratch test.The expression level of microRNA-199a/b-3p was detected by quantitative real-time polymerase chain reaction.Results After medication,the apoptosis rates in control group,parecoxib group,adriamycin group and combined medication group were respectively(4.73±0.58)%,(18.95±2.17)%,(16.74±2.08)%and(53.25±6.53)%;the migration rates in the 4 groups were respectively(58.63±7.36)%,(41.54±4.35)%,(38.36±4.42)%and(19.17±2.23)%;the expression of microRNA-199a/b-3p in the 4 groups were respectively(0.49±0.06),(1.18±0.16),(1.22±0.13)and(1.98±0.25)2~(-ΔΔCt).Compared between the control group with the the adriamycin group,the difference was statistically significant(all P<0.05);compared between the adriamycin group with parecoxib group and combined treatment group,the differences were both statistically significant(both P<0.05).Conclusion Parecoxib combined with adriamycin can effectively inhibit the proliferation and migration of breast cancer MCF-7 cells by up-regulating the expression of microRNA-199a/b-3p and blocking cell cycle.
引文
[1]刘丹蓉.高频B超在乳腺癌早期诊断中的应用价值探讨[J].中国现代医药杂志,2016,18(12):85-87.
[2]王亚民,顾康生.环氧化酶-2表达在NK/T细胞淋巴瘤化疗耐药中的作用及其机制研究[J].安徽医科大学学报,2014,49(8):1039-1044.
[3]韩惠,张卿.环氧化酶-2及其抑制剂与肿瘤耐药的研究进展[J].中国疗养医学,2015,24(4):360-363.
[4]谢晨烨,张凤,程卉,等.新藤黄酸联合表柔比星诱导人乳腺癌MCF-7细胞凋亡的研究[J].安徽中医药大学学报,2015,34(1):51-55.
[5]胡春梅,张懿敏,匡军秀,等.内、外源性趋化因子CCL5对MCF-7细胞增殖能力影响的比较[J].临床外科杂志,2013,21(6):433-435.
[6]李妍,王海,张铎,等.碘化丙啶染色流式细胞术分析肿瘤细胞凋亡的方法学探讨[J].中国实验诊断学,2012,16(5):799-800.
[7]陈霄霄,刘晓旺,周志刚,等.二烯丙基二硫下调p38活性抑制乳腺癌MCF-7细胞侵袭和转移[J].南方医科大学学报,2016,36(6):814-818.
[8]马大昌,陈诚,吴多明,等.miR-199a-3p在乳腺癌中的表达及其作用[J].中国癌症杂志,2016,26(6):481-486.
[9]罗年安,屈亚琦,董瑞.乳腺癌的治疗进展[J].现代生物医学进展,2015,15(1):160-162.
[10]袁建梅,石学军.环氧合酶2抑制剂在乳腺癌预防与治疗中的作用[J].中国药房,2016,27(5):713-717.
[2]王亚民,顾康生.环氧化酶-2表达在NK/T细胞淋巴瘤化疗耐药中的作用及其机制研究[J].安徽医科大学学报,2014,49(8):1039-1044.
[3]韩惠,张卿.环氧化酶-2及其抑制剂与肿瘤耐药的研究进展[J].中国疗养医学,2015,24(4):360-363.
[4]谢晨烨,张凤,程卉,等.新藤黄酸联合表柔比星诱导人乳腺癌MCF-7细胞凋亡的研究[J].安徽中医药大学学报,2015,34(1):51-55.
[5]胡春梅,张懿敏,匡军秀,等.内、外源性趋化因子CCL5对MCF-7细胞增殖能力影响的比较[J].临床外科杂志,2013,21(6):433-435.
[6]李妍,王海,张铎,等.碘化丙啶染色流式细胞术分析肿瘤细胞凋亡的方法学探讨[J].中国实验诊断学,2012,16(5):799-800.
[7]陈霄霄,刘晓旺,周志刚,等.二烯丙基二硫下调p38活性抑制乳腺癌MCF-7细胞侵袭和转移[J].南方医科大学学报,2016,36(6):814-818.
[8]马大昌,陈诚,吴多明,等.miR-199a-3p在乳腺癌中的表达及其作用[J].中国癌症杂志,2016,26(6):481-486.
[9]罗年安,屈亚琦,董瑞.乳腺癌的治疗进展[J].现代生物医学进展,2015,15(1):160-162.
[10]袁建梅,石学军.环氧合酶2抑制剂在乳腺癌预防与治疗中的作用[J].中国药房,2016,27(5):713-717.